Effects of TNFalpha, NOS3, MDR1 Gene Polymorphisms on Clinical Parameters, Prognosis and Survival of Multiple Myeloma Cases |
Basmaci, C
(Department of Hematology, Gaziantep University Faculty of Medicine)
Pehlivan, M (Department of Hematology, Gaziantep University Faculty of Medicine) Tomatir, AG (Department of Medical Biology, Pamukkale University, Faculty of Medicine) Sever, T (Department of Medical Biology and Genetics, Gaziantep University Faculty of Medicine) Okan, V (Department of Hematology, Gaziantep University Faculty of Medicine) Yilmaz, M (Department of Hematology, Gaziantep University Faculty of Medicine) Oguzkan-Balci, S (Department of Medical Biology and Genetics, Gaziantep University Faculty of Medicine) Pehlivan, S (Department of Medical Biology, Istanbul University, Istanbul Medical Faculty) |
1 | Akcali A, Pehlivan S, Pehlivan M, et al (2010). TNF-alpha promoter polymorphisms in multiple sclerosis: no association with -308 and -238 alleles, but the -857 alleles in associated with the disease in Turkish patients. Int J Immunogenet, 37, 91-5. DOI |
2 | Banu C, Moise A, Arion CV, et al (2011). Cytokine Gene Polymorphisms support diagnostic monitoring of Romanian Multiple Myeloma patients. J Med Life, 4, 264-8. |
3 | Bivalacqua TJ, Champion HC, Hellstrom WJG (2002). Implications of nitric oxide synthases isoforms in the pathophysiology of Peyronie’s disease. Int J Imp Res, 14, 345-2. DOI |
4 | Black RA, Rauch CT, Kozlosky CJ, et al (1997). A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature, 385, 729-33. DOI |
5 | Buda G, Maggini V, Galimberti S, et al (2007). MDR1 polymorphism influences the outcome of multiple myeloma patients. Br J Haematol. 137, 454-6. DOI |
6 | Buda G, Ricci D, Huang CC, et al (2010). Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol. 89, 1133-40. DOI |
7 | Cox DR (1972). Regression models and life-tables. J R Stat Soc Ser B, 34, 187-220. |
8 | Dogra S, Khullar G (2013). Tumor necrosis factor- antagonists: Side effects and their management. Indian J Dermatol Venereol Leprol, 7, 35-46. |
9 | Drain S, Catherwood MA, Orr N, et al (2009). ABCB1 (MDR1) rs1045642 is associated with increased overall survival in plasma cell myeloma. Leuk Lymphoma, 50, 566-570. DOI |
10 | Du J, Yuan ZG, Zhang CY, et al (2009). Effect of TNF-alpha gene polymorphism on outcome of thalidomide-based regimens for multiple myeloma. Zhonghau Xue Ye Xeu Za Zhi, 30, 649-53. |
11 | Game X, Rischmann P, Arnal JF, et al (2013). Nitric oxide pathway and female lower urinary tract. Physiological and pathophysiological role]. Prog Urol, 23, 926-35. DOI |
12 | Germann, UA (1996). P-glycoprotein--a mediator of multidrug resistance in tumour cells. Eur J Cancer. 32, 927-44. DOI |
13 | Ghilardi G, Biondi ML, Cecchini F, et al (2003). Vasculer invasion in human breast cancer is coralated to T->786C polymophism of NOS3 gene. Nitric Oxide, 9, 118-22. DOI |
14 | Hefler LA, Grimm C, Lantzsch T, et al (2006). Polymorphisms of the endothelial nitric oxide synthase gene in breast cancer. Breast Cancer Res Treat, 98, 151-55. DOI |
15 | Hefler LA, Ludwig E, Lampe D, et al (2002). Polymorphisms of the endothelial nitric oxide synthase gene in ovarian cancer. Gynecol Oncol, 86,134-37. DOI |
16 | Heil M, Eitenmuller I, Schmitz-Rixen T, et al (2006). Arteriogenesis versus angiogenesis: similarities and differences. J Cell Mol Med, 10, 45-55. DOI |
17 | Ichimaru M, Ishimaru T, Mikami M, et al (1982). Multiple myeloma among atomic bomb survivors in Hiroshima and Nagasaki, 1950-76: Relationship to radiation dose absorbed by marrow. J Natl Cancer Inst, 69, 323-28. |
18 | Iokupova EV, Grinchuk OV, Kalimullina DKh, et al (2003). Molecular genetic analysis of the IL-6 and Tumor necrosis factor alpha gene polymorphisms in multiple myeloma. Mol Biol (Mosk), 37, 420-24. |
19 | Juliano RL, Ling VA (1976). Surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta, 455, 152-62. DOI |
20 | Jamroziak K, Balcerczak E, Cebula B, et al (2005). Multi-drug transporter MDR1 gene polymorphism and prognosis in adult acute lymphoblastic leukemia. Pharmacol Rep, 57, 882-8. |
21 | Kadar K, Kovacs M, Karadi I, et al (2008). Polymorphism of TNF-alpha and LT-alpha genes in multiple myeloma. Leuk Res. 32, 1499-504. DOI |
22 | Kaplan EL, Meier P (1958). Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53, 457-81. DOI |
23 | Knop S (2014). The multiple myeloma - current view and perspectives. Med Monatsshr Pharm, 37, 84-92. |
24 | Kyle RA (1994). Multiple myeloma: How did it begin? Mayo Clin Proc, 69, 680-83. DOI |
25 | Medeiros R, Morais A, Vasconcelos A, et al (2002). Endothelial nitric oxide synthase gene polymorphisms and genetic susceptibility to prostate cancer. Eur J Cancer Prev, 11, 343-50. DOI |
26 | Nakamura K, Matsuzawa N, Ohmori S, et al (2013). Clinical Evidence of Pharmacokinetic Changes in Thalidomide Therapy. Drug Metab Pharmacokinet, 28, 38-43. DOI |
27 | Nathan C, Xie QW (1994). Nitric oxide synthases. Roles, tolls and controls. Cell, 78, 915-8. DOI |
28 | Neben K, Mytilineos J, Moehler TM, et al (2002). Polymorphisms of the tumor necrosis factor- gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood, 100, 2263-65. |
29 | Riener EK, Hefler LA, Grimm C, et al (2004). Polymorphisms of the endothelial nitric oxide synthase gene in women with vulvar cancer. Gynecol Oncol, 93, 686-90. DOI |
30 | Olmos G, Llado J (2014). Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity. Mediators Inflamm, 2014, 861231. |
31 | Wajant H, Pfizenmaier K, Scheurich P (2003). Tumor necrosis factor signaling. Cell Death Differ, 10, 45-65. DOI |
32 | Wang SS, Davis S, Cerhan JR, et al (2006). Polymorphisims in oxidative stres genes and risk for non-Hodgkin lymphoma. Carcinogenesis, 27, 1828-34. DOI |